Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

Sponsor
National University Hospital, Singapore
Study ID
NCT06211868
Status
Recruiting
Apply to this trial

Conditions

  • Cardiovascular Diseases
  • Metabolic Syndrome
  • Non-Alcoholic Fatty Liver Disease

Eligibility Criteria

Sex
ALL
Age
40 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Digital wearable and AI-human symbiotic lifestyle intervention — BEHAVIORAL
    Digital wearable and AI-human symbiotic lifestyle intervention

Study Details

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Key Dates

First listed
Jan 18, 2024
Start date
Mar 1, 2024
Status verified
Jan 2024
Primary completion
Sep 1, 2029
Completion
Sep 1, 2030

Study Design

Enrollment
3,000 participants (estimated)

Arms

  • Arm: Observational cohort
  • Arm: Randomised cohort

Primary Outcome Measure

Major adverse cardiovascular event [ Time Frame: 5 years ]

Central Contacts

Related Studies